Oncotarget

Reviews:

The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications

Haiyan Zhu, Xuejie Zhu, Lihong Zheng, Xiaoli Hu, LuZhe Sun and Xueqiong Zhu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:29395-29405. https://doi.org/10.18632/oncotarget.12561

Metrics: PDF 1710 views  |   HTML 2653 views  |   ?  


Abstract

Haiyan Zhu1, Xuejie Zhu2, Lihong Zheng1, Xiaoli Hu1, LuZhe Sun3 and Xueqiong Zhu1

1 Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

2 Department of Gynecology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

3 Department of Cellular & Structural Biology, the University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Correspondence to:

Xueqiong Zhu, email:

Keywords: ovarian cancer, androgen receptor, clinical implications

Received: June 06, 2016 Accepted: September 25, 2016 Published: October 11, 2016

Abstract

Ovarian cancer is the major cause of death in women with gynecologic malignancies. There is emerging evidence that Androgen/androgen receptor (AR) signaling plays a critical role in the etiology and progression of this disease. Androgen receptor is frequently expressed in various subtypes of ovarian cancers and androgen/AR signaling has been shown to promote proliferation, migration, and invasion of ovarian cancer cells. Furthermore, shorter AR CAG repeats length and increased AR activity are associated with increased ovarian cancer risk and may be a useful prognosticator under certain circumstances. Here, we summarize current findings regarding the role of the AR in ovarian cancer and discuss agents that target this pathway as potential therapeutics for ovarian cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12561